NASDAQ: OMER · Life Sciences · 4 alerts · CIK 1285819
Share price
$16.68Close, Nov 16
Market cap
$1.24B
Shares outstanding
74.46MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Omeros Corp filings on SEC EDGAR ↗
Omeros reported strong Yard-Temlia momentum with $35.9M net sales and positive operating cash flow, though European regulatory setbacks and a refusal to provide 2027 guidance remain key overhangs.
Omeros Corporation reported Q3 2026 financial results, highlighted by a 26% sequential increase in net revenue for YARTEMLEA to $35.9 million. The company reported a GAAP net loss of $57.4 million, primarily driven by a $62.0 million non-cash mark-to-market adjustment on convertible notes, while achieving positive operating cash flow of $13.3 million.
Term
Q3 2026
“YARTEMLEA sales continued to grow during the third quarter, delivering consecutive quarters of positive operating cash flow. As expected, 340B participation increased, reflecting substantial expansion of our customer base and increased outpatient use of YARTEMLEA. That momentum has continued into the fourth quarter, with YARTEMLEA revenues continuing to grow.”
Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief Executive Officer
Omeros Corporation granted a performance-based stock option award to CEO Gregory A. Demopulos for up to 500,000 shares at an exercise price of $17.88. The award vests across four tranches tied to stock-price hurdles ranging from $25.00 to $40.00 per share and requires continued service over a four-year period. The grant is intended to incentivize long-term shareholder value creation following the company's recent strategic milestones, including FDA approval of YARTEMLEA.
Omeros VP, Finance & CAO David J. Borges Sells $419K of Stock
David J. Borges, VP, Finance & CAO, sold 20,000 shares of Omeros Corp at $20.95 a share, worth $419K in total between Sep 22, 2026 and Sep 23, 2026. Shares held after the trade: 0 (-100.0%).